Clinical Use of PPARγLigands in Cancer

Abstract

The role of PPARγin adipocyte differentiation has fueled intense interest in the function of this steroid nuclear receptor for regulation of malignant cell growth and differentiation. Given the antiproliferative and differentiating effects of PPARγligands on liposarcoma cells, investigation of PPARγexpression and ligand activation in other solid tumors such as breast, colon, and prostate cancers ensued. The anticancer effects of PPARγligands in cell culture and rodent models of a multitude of tumor types suggest broad applicability of these agents to cancer therapy. This review focuses on the clinical use of PPARγligands, specifically the thiazolidinediones, for the treatment and prevention of cancer.